Editas Medicine (EDIT) Stock Forecast & Price Target

$3.04 +0.04 (+1.33%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$3.11 +0.07 (+2.30%)

As of 08:49 AM Eastern

Compare

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
1

Hold
1

Buy
5

Based on 7 Wall Street analysts who have issued ratings for Editas Medicine in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, and 5 have given a buy rating for EDIT.

Consensus Price Target

$5.40
77.63% Upside

According to the 7 analysts' twelve-month price targets for Editas Medicine, the average price target is $5.40. The highest price target for EDIT is $8.00, while the lowest price target for EDIT is $4.00. The average price target represents a forecasted upside of 77.63% from the current price of $3.04.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for EDIT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Editas Medicine and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EDIT Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	9 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$5.40	$5.30	$5.00	$6.54
Forecasted Upside	77.63% Upside	94.85% Upside	200.30% Upside	391.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

EDIT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Editas Medicine Stock vs. The Competition

Type	Editas Medicine	Medical Companies	S&P 500
Consensus Rating Score	2.57	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	77.63% Upside	938.17% Upside	14.75% Upside
News Sentiment Rating	Neutral News See Recent EDIT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/5/2026	Chardan Capital 2 of 5 stars	Geulah Livshits 4 of 5 stars	Boost Target	Buy	$3.50 ➝ $4.00	+31.58%
4/20/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (E+)
3/10/2026	JonesTrading 3 of 5 stars	Soumit Roy 1 of 5 stars	Upgrade	Hold ➝ Buy	$8.00	+206.51%
3/9/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$6.00	+158.62%
3/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
9/5/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mitchell S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$5.00	+98.41%
9/3/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yanan Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$3.00 ➝ $4.00	+60.13%
4/29/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
12/16/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$7.00 ➝ $5.00	+247.22%
12/16/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Neutral ➝ Underweight

12/13/2024	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Sector Perform	$5.00 ➝ $4.00	+166.67%
12/13/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Equal Weight	$5.00 ➝ $3.00	+92.93%
12/13/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$11.00 ➝ $3.00	+58.73%
12/13/2024	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/25/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Underperform	$13.00 ➝ $1.00	-59.02%
11/4/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Seedhouse Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
6/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform	$12.00 ➝ $12.00	+138.57%
5/9/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$16.00 ➝ $15.00	+174.22%
5/9/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$7.00	+39.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:50 AM ET.

EDIT Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Editas Medicine is $5.40, with a high forecast of $8.00 and a low forecast of $4.00.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There is currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares.
: According to analysts, Editas Medicine's stock has a predicted upside of 77.63% based on their 12-month stock forecasts.
: Over the previous 90 days, Editas Medicine's stock had 1 upgrade by analysts.
: Editas Medicine has been rated by research analysts at Chardan Capital, JonesTrading, Robert W. Baird, TD Cowen, and Weiss Ratings in the past 90 days.
: Analysts like Editas Medicine more than other "medical" companies. The consensus rating for Editas Medicine is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EDIT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Editas Medicine Recommendations

This page (NASDAQ:EDIT) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Stock Forecast & Price Target

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EDIT Analyst Ratings Over Time

EDIT Analyst Recommendations By Month

EDIT Price Targets by Month

Editas Medicine Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

EDIT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Editas Medicine Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Stock Forecast & Price Target

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EDIT Analyst Ratings Over Time

EDIT Analyst Recommendations By Month

EDIT Price Targets by Month

Editas Medicine Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

EDIT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Editas Medicine Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools